Nonsteroidal anti-inflammatory drugs for retinal neurodegenerative diseases
•Nonsteroidal anti-inflammatory drugs help treat retinal neurodegenerative diseases.•Evidence of the efficacy of topical formulations of these drugs is abundant.•These drugs are still not widely used.•These drugs may help improve the treatment of retinal degenerative diseases. Nonsteroidal anti-infl...
Gespeichert in:
Veröffentlicht in: | Prostaglandins & other lipid mediators 2021-10, Vol.156, p.106578, Article 106578 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Nonsteroidal anti-inflammatory drugs help treat retinal neurodegenerative diseases.•Evidence of the efficacy of topical formulations of these drugs is abundant.•These drugs are still not widely used.•These drugs may help improve the treatment of retinal degenerative diseases.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most common prescription drugs for inflammation, and topical NSAIDs are often used in ophthalmology to reduce pain, photophobia, inflammation, and edema. In recent years, many published reports have found that NSAIDs play an important role in the treatment of retinal neurodegenerative diseases, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, pathological myopia, and retinitis pigmentosa (RP). The aim of the current review is to provide an overview of the role of various NSAIDs in the treatment of retinal neurodegenerative diseases and the corresponding mechanisms of action. This review highlighted that the topical application of NSAIDs for the treatment of retinal degenerative diseases has been studied to a remarkable extent and that its beneficial effects in many diseases have been proven. In the future, prospective studies with large study populations are required to extend these effects to clinical settings. |
---|---|
ISSN: | 1098-8823 |
DOI: | 10.1016/j.prostaglandins.2021.106578 |